Ginkgo Bioworks (DNA) Competitors $12.50 +0.48 (+3.95%) As of 02:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNA vs. TWST, MLYS, OCUL, BEAM, IDYA, ANIP, BLTE, AGIO, GLPG, and TARSShould you be buying Ginkgo Bioworks stock or one of its competitors? The main competitors of Ginkgo Bioworks include Twist Bioscience (TWST), Mineralys Therapeutics (MLYS), Ocular Therapeutix (OCUL), Beam Therapeutics (BEAM), IDEAYA Biosciences (IDYA), ANI Pharmaceuticals (ANIP), Belite Bio (BLTE), Agios Pharmaceuticals (AGIO), Galapagos (GLPG), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "pharmaceutical products" industry. Ginkgo Bioworks vs. Its Competitors Twist Bioscience Mineralys Therapeutics Ocular Therapeutix Beam Therapeutics IDEAYA Biosciences ANI Pharmaceuticals Belite Bio Agios Pharmaceuticals Galapagos Tarsus Pharmaceuticals Twist Bioscience (NASDAQ:TWST) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment. Is TWST or DNA more profitable? Twist Bioscience has a net margin of -23.51% compared to Ginkgo Bioworks' net margin of -136.56%. Twist Bioscience's return on equity of -29.03% beat Ginkgo Bioworks' return on equity.Company Net Margins Return on Equity Return on Assets Twist Bioscience-23.51% -29.03% -21.77% Ginkgo Bioworks -136.56%-43.25%-22.29% Does the media favor TWST or DNA? In the previous week, Twist Bioscience had 3 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 4 mentions for Twist Bioscience and 1 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 1.82 beat Twist Bioscience's score of 0.68 indicating that Ginkgo Bioworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ginkgo Bioworks 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has better valuation & earnings, TWST or DNA? Twist Bioscience has higher revenue and earnings than Ginkgo Bioworks. Twist Bioscience is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTwist Bioscience$312.97M5.36-$208.73M-$1.45-19.18Ginkgo Bioworks$227.04M3.26-$547.03M-$5.86-2.13 Do analysts prefer TWST or DNA? Twist Bioscience presently has a consensus price target of $49.40, suggesting a potential upside of 77.63%. Ginkgo Bioworks has a consensus price target of $9.00, suggesting a potential downside of 28.03%. Given Twist Bioscience's stronger consensus rating and higher possible upside, equities research analysts clearly believe Twist Bioscience is more favorable than Ginkgo Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Twist Bioscience 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.73Ginkgo Bioworks 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders and institutionals hold more shares of TWST or DNA? 78.6% of Ginkgo Bioworks shares are held by institutional investors. 3.0% of Twist Bioscience shares are held by company insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, TWST or DNA? Twist Bioscience has a beta of 2.31, indicating that its stock price is 131% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. SummaryTwist Bioscience beats Ginkgo Bioworks on 12 of the 16 factors compared between the two stocks. Get Ginkgo Bioworks News Delivered to You Automatically Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNA vs. The Competition Export to ExcelMetricGinkgo BioworksMED IndustryMedical SectorNYSE ExchangeMarket Cap$728.16M$3.14B$5.74B$21.66BDividend YieldN/A2.36%5.61%3.51%P/E Ratio-2.1021.1176.7430.09Price / Sales3.26449.73552.0060.69Price / CashN/A44.8325.8118.30Price / Book0.959.8013.644.65Net Income-$547.03M-$52.73M$3.29B$1.00B7 Day Performance17.86%2.77%1.89%1.14%1 Month Performance-0.02%5.05%4.26%2.93%1 Year Performance59.50%16.64%80.80%15.27% Ginkgo Bioworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNAGinkgo Bioworks1.4269 of 5 stars$12.51+3.9%$9.00-28.0%+50.6%$728.16M$227.04M-2.10640Positive NewsTWSTTwist Bioscience3.7862 of 5 stars$25.72+1.6%$49.40+92.1%-40.1%$1.55B$312.97M-17.74990MLYSMineralys Therapeutics2.801 of 5 stars$36.21-2.4%$43.50+20.1%+231.2%$2.40BN/A-10.1728OCULOcular Therapeutix3.9055 of 5 stars$12.54-2.1%$17.83+42.2%+35.9%$2.18B$56.66M-9.80230Positive NewsGap UpBEAMBeam Therapeutics2.9801 of 5 stars$21.28+3.3%$46.40+118.0%-4.8%$2.15B$63.52M-4.73510IDYAIDEAYA Biosciences3.986 of 5 stars$24.53-0.3%$42.85+74.7%-25.9%$2.15B$7M-6.4780ANIPANI Pharmaceuticals4.0304 of 5 stars$98.81+1.1%$88.25-10.7%+60.8%$2.14B$747.40M-128.32600BLTEBelite Bio2.8123 of 5 stars$66.80-3.9%$96.00+43.7%+47.2%$2.13BN/A-43.1010Analyst UpgradeHigh Trading VolumeAGIOAgios Pharmaceuticals4.2657 of 5 stars$36.30-1.3%$56.00+54.3%-18.0%$2.11B$40.88M3.30390GLPGGalapagos0.1505 of 5 stars$31.88-0.4%$26.00-18.4%+13.1%$2.10B$275.61M0.001,310News CoverageTARSTarsus Pharmaceuticals2.2024 of 5 stars$49.59+0.5%$66.67+34.4%+61.2%$2.09B$182.95M-21.2850Positive News Related Companies and Tools Related Companies Twist Bioscience Competitors Mineralys Therapeutics Competitors Ocular Therapeutix Competitors Beam Therapeutics Competitors IDEAYA Biosciences Competitors ANI Pharmaceuticals Competitors Belite Bio Competitors Agios Pharmaceuticals Competitors Galapagos Competitors Tarsus Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:DNA) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredRefund From 1933: Trump’s Reset May Create Instant WealthTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ginkgo Bioworks Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ginkgo Bioworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNA Stock Alerts